REMAP-CAP: NEW RESULTS FROM THE ACE2 RAS DOMAIN!
New results have recently been published from the ACE2 RAS domain, one of the multiple therapeutic domains within REMAP-CAP, a trial within Spiral’s manifest of studies.
Better Health Outcomes Together - The PANORAMIC Case Study with Lead Statistician Ly-Mee Yu
Spiral talks with Ly-Mee Yu, Lead Statistician of the PANORAMIC Trial on the devastating effects of the pandemic and how trials like PANORAMIC, with the help of Spiral’s software, are aiming to provide better health outcomes for those affected by the virus.
Meet Mel - Spiral’s newest project manager
Meet Mel, the newest project manager to join our Spiral team. Mel has only been with us a few weeks but has settled into her role marvellously, bringing with her a background in project and account management as well as her recently acquired skills and knowledge in development.
The Panoramic Trial Reaches 20,000 Enrolments!
Over ten thousand participants from right across the UK have now taken part in the NIHR-funded and supported PANORAMIC trial - the world’s largest study into new antiviral treatments against COVID-19 in community, ambulatory care.
REMAP-CAP reaches new milestone
REMAP-CAP, the Randomised, Embedded, Multi-factorial, Adaptive Platform Trial for Community-Acquired Pneumonia, has recently hit a significant date in its trial history, celebrating two years since the first Covid-19 ICU patient was randomised into the trial.
Spiral joins first of its kind clinical trial - continuing the fight against COVID
Spiral is pleased to announce our involvement in another incredibly exciting trial, aimed at producing effective Covid-19 treatments for critical care patients.
Full-dose blood thinners benefit moderately ill COVID-19 patients
REMAP-CAP an application in Spiral’s study manifest, has recently been used in a collaborative clinical trial that focused on identifying effective treatments for critically ill Covid-19 patients.